1 “... difference [SMD] 0.33, 95% CI 0.56 to 0.09) (SOE: low), and risk of surgery at short-term followup (relative...”

2 “... difference [SMD] 0.33, 95% CI 0.56 to 0.09) (SOE: low), and risk of surgery at short-term followup (relative...”

3 “... was the most commonly reported outcome, followed by back-specific function. When present, observed benefits...”

4 “... was the most commonly reported outcome, followed by back-specific function. When present, observed benefits...”

5

6 “...4.9%, RR, 1.47, 95% CI 1.19 to 1.80); other serious harms were infrequent, with no differences...”

7 “... to understand long-term benefits, risk of abuse and related outcomes, and effectiveness of different opioid...”

8 “... to understand long-term benefits, risk of abuse and related outcomes, and effectiveness of different opioid...”

9

10 “...) and few harms relative to older antiviral therapies. An SVR after antiviral therapy is associated...”

11 “...) and few harms relative to older antiviral therapies. An SVR after antiviral therapy is associated...”

12 “... small decrease in pain severity (7 RCTs, N=632, 0 to 10 scale, mean difference [MD] −0.54, 95...”